Answers are grounded in this paper and cite their sources.
Antimicrobial peptides (AMPs) defined as short peptide-chain molecules of natural or synthetic origin have emerged as a research hotspot in the field of antimicrobial drug development in recent years. This is due to their unique antibacterial mechanisms and broad-spectrum antibacterial activity. The sources of AMPs are diverse, including naturally occurring biopeptides and synthetic peptides predicted by artificial intelligence through chemical synthesis. AMPs characteristically function through the mechanisms of disrupting bacterial cell membranes, interfering with cell wall synthesis, or inhibiting key metabolic pathways. Their diverse modes of action enable them to effectively tackle the challenges posed by drug-resistant bacterial strains. Nevertheless, AMPs remain considerable challenges in clinical applications, including low bioavailability, inadequate in vivo stability, and potential toxicity concerns. To address these limitations and enhance the performance of AMPs, researchers have developed a range of modification approaches. These include sequence optimization and peptide-compound conjugation. This review focuses on recent advances in the field of AMPs research, covering their diverse sources, antibacterial mechanisms, and peptide modification strategies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: